When Will Ozempic Go Generic? The Compound Patent Runs to December 2031, and the Pen Patents Run to 2041

"When will Ozempic go generic" is asked as a price question and answered, almost everywhere, as a guess. It does not have to be. The patents and exclusivity periods that decide it are published by FDA in a plain-text file, updated monthly, and anyone can read the dates out of it.

This page was written from that file — the Orange Book data files dated 11 September 2026, downloaded and read on 14 September 2026. Every date below is a field in it.

The short answer, and the number under it

One patent in the Orange Book carries a drug-substance flag against every semaglutide product Novo Nordisk sells — Ozempic injection, Ozempic tablets and Rybelsus, Wegovy injection, Wegovy tablets, all four applications, all 28 listed products.

US 8,129,343. Listed expiry: 5 December 2031.

That is the patent on the molecule. Until it lapses, nobody else can market semaglutide in the United States without licensing it or defeating it.

It is not, however, the last date in the file.

The second wall

Semaglutide's oral products run their own ladder out to 1 February 2039.

The gap between the two bolded rows is the whole commercial story of this class. Nine years and two months separate the end of the compound patent from the end of the longest patent listed on a currently marketed Ozempic presentation. Patents in that later group are not on the molecule — the drug-substance flag is blank on all of them — they are on formulations and delivery. Whether they delay a generic depends on whether a generic can be made without practising them, which is a question for litigation rather than for a data file.

The detail almost nobody reports: the patents nearest expiry have been asked to leave

Eleven patents listed against Ozempic expire between 20 January 2026 and 29 September 2027. Every single one of them carries the Orange Book's patent delist request flag.

FDA's own definition of that field, on the page that publishes these files, reads:

Sponsor has requested patent be delisted. This patent has remained listed because, under Section 505(j)(5)(D)(i) of the Act, a first applicant may retain eligibility for 180-day exclusivity based on a paragraph IV certification to this patent for a certain period.

Read that twice. Novo Nordisk has asked FDA to remove those eleven patents from the list. They are still printed, and the reason they are still printed is that a generic applicant's rights depend on them: the first company to file a paragraph IV challenge against a listed patent can earn 180 days of exclusivity as the only generic on the market, and delisting the patent out from under that filing would take the prize away.

So the near-term patent list on Ozempic is, on the public record, being maintained partly for the benefit of the companies trying to copy it. That is a real and slightly strange fact about how the Hatch-Waxman system works, it is stated by FDA in its own file documentation, and it appears on no consumer page about this question.

Exclusivity is the other clock, and it is shorter

Patents are one lock; FDA-granted exclusivity is a second, independent one. For semaglutide the entries in the September 2026 file are:

Every one of them lapses before the compound patent does. For this drug, exclusivity is not the binding constraint — the patent is.

The class already went generic. Twice. Just not this molecule.

The most useful correction on this page is not a date. It is that the question contains a false premise.

Eleven approved generic liraglutide applications sit in the Orange Book right now, from nine companies:

Generic GLP-1 injections have been approved in the United States for more than twenty months. The molecule is liraglutide — the drug behind Victoza and Saxenda, and the one that loses badly to semaglutide in the only head-to-head trial — which is exactly why nobody noticed. The class went generic on the compound people had already moved off.

Two further details in that table are worth pulling out. The codes split eight AP1 against three AP2, and those are not decoration: AP1 matches Victoza, AP2 matches Saxenda. The same molecule at the same concentration in the same pen has eight generic equivalents for its diabetes brand and three for its obesity brand. Indication decides substitutability here just as it decides who pays.

And exenatide has gone further still. Byetta at both strengths, Bydureon, Bydureon Pen and Bydureon BCise are all listed as discontinued. The only exenatide product still marketed in the United States is Amneal's generic. The brand left; the copy stayed.

Tirzepatide is not in this conversation at all

For completeness, because the question is often asked about both: there is no abbreviated application for tirzepatide in the Orange Book. Lilly holds 48 listed product entries across Mounjaro and Zepbound, including vials and KwikPens added in January 2026, and no generic applicant appears against any of them.

What this page will not tell you

It will not tell you what a generic will cost, when one will actually be dispensed, or whether a manufacturer will settle a challenge years before a patent expires — none of which is in a patent file, and all of which has decided the timing of generic entry for other drugs. It will also go out of date: the Orange Book is republished monthly, patents are added and delisted, and a challenge decided in court can move a date by years. The file used here is dated 11 September 2026 and was read on 14 September 2026.

Sources

FDA Orange Book data files (products.txt, patent.txt, exclusivity.txt), file date 11 September 2026, downloaded and parsed 14 September 2026; and FDA's published field definitions for those files, on the Orange Book Data Files page, content current as of 18 August 2026.